FBR Capital analyst William Tanner reiterated his Outperform rating and $214 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE